Background: Osteoarthritis is a major source of pain, disability, and socioeconomic cost worldwide. Osteonecrosis is a disabling disorder that frequently occurs in the younger population aged from 20-50 years. The compound Eucommia bone tonic granules, a traditional Chinese medicine, can alleviate the damage of osteoarthritis and osteonecrosis.
Aim: To investigate the potential role of the compound Eucommia bone tonic granules (Eucommia) in the treatment of patients with osteoarthritis and osteonecrosis.
Methods: One-hundred forty osteoarthritis and osteonecrosis cases admitted to our hospital from January 2013 to December 2017 were selected. Patients were divided into two groups: Eucommia-meloxicam group and meloxicam group. Clinical efficacy and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score were evaluated according to the evaluation criteria of orthopedic diseases. The levels of bone-GLA protein, interleukin-17, recombinant human S100 calcium binding protein A12, sphingosine 1-phosphate, cystatin C, creatinine, and hemoglobin in peripheral blood were determined.
Results: The total effective rate in the two osteoarthritis groups was not different, but the total effective rate in the two osteonecrosis groups was significantly different. The overall efficacy of Eucommia-meloxicam group was superior to that of the meloxicam group. WOMAC showed that pain, stiffness, and dysfunction in the two groups of osteoarthritis and osteonecrosis before and after treatment were significantly different. The concentration of recombinant human S100 calcium binding protein A12, sphingosine 1-phosphate, cystatin C, creatinine, and hemoglobin before and after treatment in the Eucommia-meloxicam group and meloxicam group of osteoarthritis and osteonecrosis were significantly different, and the two treatment groups were significantly different from each other for osteoarthritis.
Conclusion: Our findings indicate that Eucommia can effectively enhance the curative effect of meloxicam, and the combination of Eucommia and meloxicam is superior to meloxicam alone.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962075 | PMC |
| http://dx.doi.org/10.12998/wjcc.v8.i1.46 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of platelet-rich plasma in rheumatic diseases.
Rheumatol Int
December 2024
Department of Surgery and Anesthesiology-Intensive Care, Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent, Kazakhstan.
Platelet-rich plasma (PRP) has gained increasing recognition as a promising therapeutic agent in managing rheumatic diseases. Conventional treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs), primarily act on reducing inflammation but fail to address the underlying mechanisms of connective tissue degradation. PRP, an autologous preparation enriched with growth factors and bioactive molecules, is pivotal in modulating inflammation and fostering tissue regeneration.
View Article and Find Full Text PDFMetal-backed versus all-poly tibia in the original cartier unicompartmental knee arthroplasty: outcomes and survivorship at long-term follow-up.
Arch Orthop Trauma Surg
December 2024
Sezione di Chirurgia Protesica ad Indirizzo Robotico Unità di Traumatologia dello Sport, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
Purpose: Unicompartmental knee arthroplasty (UKA) is a viable option for localized osteoarthritis (OA) or avascular osteonecrosis with several advantages over total knee arthroplasty (TKA). UKA implants may feature a tibial component either all-polyethylene (AP) or metal-backed (MB). This study aims to retrospectively compare the clinical outcomes and survivorship of 74 UKAs over 16 years, focusing on comparing the results and survivorship of MB versus AP tibial tray.
View Article and Find Full Text PDFBiological Augmentation With Retro-Drilling Core Decompression in Early Stage of Femoral Head Avascular Necrosis.
Arthrosc Tech
November 2024
Department of Orthopedics and Traumatology, Ankara Etlik City Hospital, Ankara, Turkey.
Osteonecrosis of the femoral head can lead to end-stage osteoarthritis when left untreated. The incidence has been on the rise since the onset of the COVID-19 pandemic. Core decompression of the femoral head is usually the first line of surgical treatment when conservative options fail.
View Article and Find Full Text PDFPostoperative complications and cost implications in sickle cell disease patients undergoing total hip arthroplasty: A national inpatient sample study.
J Orthop
June 2025
Stony Brook University Hospital, Department of Orthopaedic Surgery, 100 Nicolls Rd, Stony Brook, NY, 11794, United States.
Background: Sickle cell disease (SCD) is a genetic condition affecting approximately 5 % of the global population, with significant prevalence in sub-Saharan Africa and an estimated 89,079 cases in the United States. Osteonecrosis, particularly of the femoral head (ONFH), is a common orthopaedic complication in SCD, often requiring total hip arthroplasty (THA) when conservative treatments fail. While THA can improve pain and function, it carries significant perioperative risks, with complication rates in patients with SCD as high as 67 %.
View Article and Find Full Text PDFEndoscopic obturator nerve radiofrequency ablation for femoral head necrosis: a case series.
Pain Manag
December 2024
Department of Orthopedic Surgery, XuZhou Central Hospital, XuZhou Clinical School of Xuzhou Medical University, Xuzhou, China.
Background: This pilot case series evaluated the feasibility and effectiveness of using endoscopic radiofrequency ablation (RFA) of the articular branch of the anterior obturator nerve under endoscopic and fluoroscopic guidance for controlling pain in patients with osteonecrosis of the femoral head (ONFH).
Methods: Data on 11 consecutive patients were collected with ONFH underwent endoscopic RFA of the anterior obturator nerve. Electromyography (EMG) examination was performed preoperatively and postoperatively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!